Today, the Interim VP, Finance, and CFO of SurModics (NASDAQ: SRDX), Timothy Arens, sold shares of SRDX for $344.4K.
Following Timothy Arens’ last SRDX Sell transaction on March 07, 2016, the stock climbed by 29.7%. In addition to Timothy Arens, one other SRDX executive reported Sell trades in the last month.
See today’s analyst top recommended stocks >>
Based on SurModics’ latest earnings report for the quarter ending March 31, the company posted quarterly revenue of $19.06 million and quarterly net profit of $1.53 million. In comparison, last year the company earned revenue of $17.5 million and had a net profit of $506K. SRDX’s market cap is $656.4M and the company has a P/E ratio of 707.86. Currently, SurModics has an average volume of 82.65K.
The insider sentiment on SurModics has been negative according to 51 insider trades in the past three months. This sentiment is lower than the average sentiment of company insiders in this sector.
Company insider trades are published daily on the SEC (Securities and Exchange Commission). DailyInsider’s proprietary algorithm analyzes these trades and selects the most attractive stocks based on influential insider trades each day. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
SurModics, Inc. engages in the provision of medical device and in vitro diagnostic technologies to the healthcare industry. It operates through the Medical Device and In Vitro Diagnostics segments.
